Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 869858 | ISIN: FR0000125338 | Ticker-Symbol: CGM
Tradegate
15.01.25
15:00 Uhr
158,20 Euro
+2,95
+1,90 %
1-Jahres-Chart
CAPGEMINI SE Chart 1 Jahr
5-Tage-Chart
CAPGEMINI SE 5-Tage-Chart
RealtimeGeldBriefZeit
157,90158,0015:04
157,95158,0015:03
GlobeNewswire (Europe)
324 Leser
Artikel bewerten:
(2)

Capgemini SE: Capgemini announces two leadership appointments

Finanznachrichten News

Media relations:
Sam Connatty
Tel.: +44 (0)370 904 3601
Email: sam.connatty@capgemini.com

Capgemini announces two leadership appointments

  • Paul Margetts becomes CEO of the Asia Pacific Strategic Business Unit
  • Rob Walker replaces Paul Margetts as MD of Capgemini's UK Business Unit

Paris, September 6, 2024: Capgemini today announced two key leadership appointments in APAC and the UK respectively. Paul Margetts, formerly MD of the UK Business Unit, becomes CEO of Capgemini's Asia Pacific Strategic Business Unit effective October 1, 2024. He replaces Olaf Pietschner, who will take on the new role of Chief Revenue Officer in APAC. Rob Walker has replaced Paul, as MD of the UK Business Unit, effective September 2, 2024.

"Paul Margetts has successfully steered a highly resilient UK business to deliver strong performance in the last few years. He has been a champion of our journey towards Net Zero and an exemplar of our commitment to inclusion and social value. In his new role, Paul will bring his strong track record and business acumen to the Asia Pacific region, a key growth area for the Group," comments Aiman Ezzat, CEO of the Capgemini Group. "I am also very happy to welcome Rob Walker to Capgemini. He has a wealth of experience and deep industry knowledge in key sectors. Rob is also passionate about supporting clients in driving growth through technology innovation and building high-performance teams. I know he will add great value to the UK Business Unit's next chapter of development. I wish Paul and Rob every success in their new positions."

Biography: Paul Margetts
Paul was MD of the UK Business Unit between 2018 and 2024. He has been a member of the Group Executive Committee since 2018.
From 2015, Paul was CEO, Application Services UK, member of the UK Country Board, and Capgemini Saudi Arabia Board.
Paul has been with the Capgemini Group since 1992 during which time he has led and delivered complex engagements for clients across multiple sectors in the UK and Europe. He's been also responsible for leading significant delivery, sales and technology operations, and for driving change across the business.
Biography: Rob Walker

Rob spent 25 years at EY helping clients improve the efficiency of their businesses using emerging technologies and digital capabilities. In 2021, he joined Cognizant as Managing Director of the UK & Ireland business. Moving to become President of Global Growth Markets, he played an integral part in helping to globalize Cognizant's business, growing the company's revenue across targeted geographies and accelerating growth in digital internationally.

Note to Editors
High-resolution photography of Paul Margetts and Rob Walker is available on request.

About Capgemini
Capgemini is a global business and technology transformation partner, helping organisations to accelerate their dual transition to a digital and sustainable world while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fuelled by its market-leading capabilities in AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2023 global revenues of €22.5 billion.

Get the future you want | www.capgemini.com


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.